Abstract
Peroxisome proliferator-activated receptor (PPAR)-α, a member of a large nuclear receptor superfamily, plays a major role in the regulation of lipid metabolism. Recently, PPARαactivation has been shown to confer additional benefits on endothelial function, kidney function, and anti-inflammation, suggesting that PPARαagonists may be good candidates for treating acute renal failure. In clinical application, PPAR-αactivators, such as hypolipidemic drugs in fibric acid class, were proven to have therapeutic effects on metabolic syndrome and cardiovascular disease. This paper focuses on signaling pathways, ligand selectivity, and physio-pathological roles of PPARαin kidney diseases and the therapeutic utility of PPARαmodulators in the treatment of diabetes and inflammation-induced nephropathy. Implication of new and more potent PPAR-αactivators could provide important insights into the overall benefits of activating PPAR-αclinically for the treatment of dyslipidemia and the prevention of diabetic or inflammation-induced nephropathy in the future.
Funding Information
  • Tzu Chi University (TCIRP 95007-01, TCIRP 95007-02, TCRD-TPE-95-15, TCRD-I 9801-01)
  • Tzu Chi University (TCIRP 95007-01, TCIRP 95007-02, TCRD-TPE-95-15, TCRD-I 9801-01)
  • Tzu Chi Hospital (TCIRP 95007-01, TCIRP 95007-02, TCRD-TPE-95-15, TCRD-I 9801-01)
  • Tzu Chi Hospital (TCIRP 95007-01, TCIRP 95007-02, TCRD-TPE-95-15, TCRD-I 9801-01)

This publication has 44 references indexed in Scilit: